cdc-rfa-dd10-1016 final 03 26 10.doc

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC) Population based surveillance for Deep Vein Thrombosis and Pulmonary Embolism

I. AUTHORIZATION AND INTENT

Announcement Type: New – Type 1 Funding Opportunity Number: CDC- RFA-DD10-1016 Catalog of Federal Domestic Assistance Number: 93.184 Key Dates:

Letter of Intent Deadline Date: April 26, 2010 on www.Grants.gov

Application Deadline Date: May 11, 2010 on Grants.gov, 11:59pm Eastern Standard Time Authority:

This program is authorized under Sections 301(a) [42 USC 241(a)] and 317 (C) of the Public Health Service Act [42 U.S.C. Sections 243, 247b(k)(2) and 247b-4] as amended.

Background:

Venous thromboembolism (VTE) is a condition in which the venous blood clots inappropriately (i.e., too much), causing severe morbidity and mortality. The term VTE is a continuum, encompassing both deep vein thrombosis (DVT), clots in the deep veins of the body, and pulmonary embolism (PE), which occurs when a clot breaks free and enters the arteries of the lungs. The precise number of people affected by DVT and PE is unknown. The estimated annual incidence of VTE (either new or recurrent DVT or PE) in the United States has ranged from 250,000 cases through 1998, to more recent estimates of approximately 900,000 cases.

DVT and PE affect all races and ethnicities, ages, and both sexes and with many of the known risk factors—advanced age, immobility, surgery, obesity—increasing in society, VTE is an important and growing public health problem. In recognition, the Surgeon General released a Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism - 2008, urging all a coordinated, multifaceted plan to reduce the numbers of cases of deep vein thrombosis and pulmonary embolism nationwide.

Presently, there is no national surveillance for DVT and PE, and current prevalence and incidence estimates are likely underestimates. Because prevalence studies have focused mainly on patients of white race, the risks—and more importantly, the true burden—of DVT and PE on minority populations is unknown and unaccounted for in current estimates. Furthermore, PE often presents as sudden death. Given that autopsy rates in the United States are low, and PE may be misdiagnosed as heart failure, current estimates of the actual number of PE events are probably inaccurate and underreported. Similarly, because DVT has many presentations and is diagnosed and cared for by multiple providers and in multiple settings (inpatient and outpatient), the overall burden of DVT is likely to be underestimated as well.

Public health surveillance is the ongoing, systematic collection, analysis, and interpretation of health data that is essential to the planning, implementation, and evaluation of public health practice. The purpose of public health surveillance is to assess public health status, define public health priorities, evaluate programs, and stimulate research. Given the complexity and diversity of VTE diagnosis, care, and presentation, a multifaceted system that includes a series of focused, targeted surveillance efforts with the ability to link, evaluate, and collect data from multiple sources is needed. Our goal is a comprehensive system that includes both active and passive surveillance activities utilizing and integrating multiple data sources that can objectively capture outpatient, inpatient, and death-related events in addition to being able to distinguish an incident (first) event versus a recurrent one.

As a first step, CDC seeks to develop pilot population-based DVT and PE surveillance systems and assess their ability to meet the following objectives:

a. Describe and establish US population based estimates of VTE burden and characteristics by age, race, and gender;

b. Monitor and describe associated morbidity and mortality;

c. Monitor trends over time and evaluate outcomes, recurrence, and the effect of prevention measures;

d. Identify and generate hypotheses for further public health research;

The pilot programs will serve to not only guide future DVT and PE surveillance activities but also to aid in our comprehensive public health approach to preventing morbidity and mortality and reducing burden from VTE. Surveillance of DVT and PE will help us to better understand where to focus research and target prevention measures while also providing a much-needed baseline upon which to assess the effectiveness of prevention efforts.

Purpose:

The purpose of the program is to develop and evaluate pilot programs for population based surveillance of deep vein thrombosis and pulmonary embolism. Given the complexity of diagnosis and care of DVT and PE, CDC is evaluating models and methods to effectively and validly estimate the public health burden of DVT and PE in the United States.

This program addresses the “Healthy People 2010” focus area(s) of

· Public health infrastructure, health communication, disability and secondary conditions, access to quality health services

· This program will also help to support proposed Healthy People 2020 objectives.

Measurable outcomes of the program will be in alignment with one (or more) of the following performance goal(s) for the National Center on Birth Defects and Developmental Disabilities:

· Prevent and Reduce Complications Experienced by Persons with Certain Blood Disorders

This announcement is only for non-research activities supported by CDC. If research is proposed, the application will not be reviewed. For the definition of research, please see the CDC Web site at the following Internet address: http://www.cdc.gov/od/science/regs/hrpp/researchDefinition.htm

II. PROGRAM IMPLEMENTATION

Recipient Activities:

Awardee activities for this program include all of the following:

· Data collection and reporting

a. Implement a pilot population-based surveillance system/program to ascertain confirmed cases of deep vein thrombosis and pulmonary embolism occurring in the U.S or in specific targeted populations, geographical regions, or settings (e.g. hospitalized patients, women and pregnancy, children, advanced age, etc ).

b. Generate timely population-based data with well-defined, standardized data elements.

c. Generate new data collection capacity for effective surveillance of DVT and PE.

d. Contribute de-identified, individual level data at least semiannually to CDC. Awardees can contribute data more frequently at their discretion.

· Collaboration

e. Collaborate and coordinate with CDC.

f. Involve appropriate partners, such as health care providers, payers, academic medical centers, federal, state, and local agencies and health departments, and other organizations to assist with data collection.

g. Discuss process, methods, standardization of data collection, and other project experiences with CDC and other awardees and partners.

· Data integration

h. Demonstrate/Develop capacity to link and utilize data from multiple sources to validate cases, obtain additional demographic and health related data elements, and support surveillance activities and objectives.

· Analysis and Dissemination of information

i. Analyze with CDC assistance, the surveillance data generated by the system in a timely fashion including population based burden estimates (incidence, prevalence, mortality, etc) and trends over time (morbidity, outcomes, recurrence, effect of prevention measures, etc.)

j. Disseminate, in collaboration with CDC, data on population-based surveillance for DVT and PE, to collaborating partners and organizations, other awardees, and public health and medical communities through appropriate means including but not limited to manuscripts, surveillance reports, and newsletters.

k. Communicate information on project activities and results to CDC, partners, and other awardees.

· Evaluation and progress reports

l. Assess and share with CDC and awardees, the challenges and opportunities of the pilot project including a description of the successes, problems encountered, lessons learned, potential improvements, best practices, etc.

m. With assistance of CDC, conduct an evaluation of the surveillance pilot project.

· Potential to continue above activities in years of future funding including the expansion of case catchment area, enhancement of linkages and databases, contribution of data to centralized database, dissemination of data, and other activities.

In order to achieve the intended purpose of this program, applicants must fully describe and document in the application:

· Capabilities of surveillance of DVT and PE including case definition and proposed case ascertainment methodologies.

· Characteristics of the proposed study population (e.g. age, gender, racial and ethnic distribution, and case ascertainment setting) including documentation of a racially diverse population consistent with that of the U.S. population.

· Access to DVT and PE occurrence and diagnosis data and capacity to link to other appropriate data sources (e.g. vital records, medical records, radiology reports, hospital discharge records, pharmacy records, administrative databases, etc.).

· Proposed data sources for case finding (providers, hospitals, payers, health information exchanges, administrative datasets, etc).

· Evidence of legal authority to access data sources needed to accomplish the activities in this FOA and the application, including HIPAA requirements.

· Evidence of legal authority to share de-identified data with CDC and other awardees of this Cooperative agreement.

· Established relationships and demonstration of cooperation with appropriate partners (e.g. health officials, health care providers and payers, academic medical centers specializing in these conditions, etc.).

· Management and staffing plan already in place or proposed for implementation of this program.

· Characterization of any current efforts to serve people with DVT and PE.

CDC Activities:

In a cooperative agreement, CDC staff is substantially involved in the program activities, above and beyond routine grant monitoring.

CDC activities for this program are as follows:

a. Provide advisory technical assistance

b. Assist in designing, developing, and evaluating methodologies and approaches used for population-based surveillance of DVT and PE.

c. Assist in performing data analysis and/or quality assurance verification.

d. Facilitate communication/coordination among awardees regarding standardization of procedures and tools to improve the efficiency of activities.

e. Convene awardees to support collaboration and shared learning

f. Maintain a centralized database and assist with data dissemination.

g. Assist with evaluation of the pilot project.

h. Serve as a resource for sharing data, templates, and linking to other DVT/ PE surveillance and research programs.

III. AWARD INFORMATION AND REQUIREMENTS

Type of Award: Cooperative Agreement.

Award Mechanism: U50 Fiscal Year Funds: FY 2010 Approximate Current Fiscal Year Funding: $ 900,000 Approximate Total Project Period Funding: $ 1,800,000 (This amount is an estimate, and is subject to availability of fund and includes direct and indirect costs.)

Approximate Number of Awards: 3 Approximate Average Award: $ 300,000 (This amount is for the first 12-month budget period, and includes both direct and indirect costs.)

Floor of Individual Award Range: $200,000 Ceiling of Individual Award Range: $400,000 (This ceiling is for the first 12-month budget period and both includes direct and indirect costs.)

Anticipated Award Date: September 1, 2010 Budget Period Length: 12 months Project Period Length: 2 years Throughout the project period, CDC’s commitment to continuation of awards will be conditioned on the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports), and the determination that continued funding is in the best interest of the Federal government.

IV. ELIGIBILITY

Eligible applicants that can apply for this funding opportunity are listed below:

· Nonprofit with 501C3 IRS status (other than institution of higher education)

· Nonprofit without 501C3 IRS status (other than institution of higher education)

· For-profit organizations (other than small business)

· Small, minority, and women-owned businesses

· Universities

· Colleges

· Research institutions

· Hospitals

· Community-based organizations

· Faith-based organizations

· Federally recognized or state-recognized American Indian/Alaska Native tribal governments

· American Indian/Alaska native tribally designated organizations

· Alaska Native health corporations

· Urban Indian health organizations

· Tribal epidemiology centers

· State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau)

· Political subdivisions of States (in consultation with States)

· Other (specify) A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a letter from the state or local government as documentation of the status is required. Attach with “Other Attachment Forms” when submitting via www.grants.gov.

SPECIAL ELIGIBILITY CRITERIA: Licensing/Credential/Permits

Cost Sharing or Matching

Cost sharing or matching funds are not required for this program.

Maintenance of Effort

Maintenance of Effort is not required for this program.

Other CDC will accept and review applications with budgets greater than the ceiling of the award range.

Special Requirements:

If the application is incomplete or non-responsive to the special requirements listed in this section, it will not be entered into the review process. The applicant will be notified the application did not meet submission requirements.

· Late applications will be considered non-responsive. See section “V. Submission Dates and Times” for more information on deadlines.

· If you are applying as a bona fide agent of a state government, you must provide a letter from the state as documentation of your status. Upload this documentation into www.Grants.gov and include as Appendix 4 of your application. Applications that fail to submit the evidence requested above will be considered non-responsive.

Note: Title 2 of the United States Code Section 1611 states that an organization described in Section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting a grant, loan, or an award.

Intergovernmental Review of Applications

The application is subject to Intergovernmental Review of Federal Programs, as governed by Executive Order (EO) 12372. This order sets up a system for state and local governmental review of proposed federal assistance applications. Contact the state single point of contact (SPOC) as early as possible to alert the SPOC to prospective applications and to receive instructions on the State’s process. Visit the following Web address to get the current SPOC list:

http://www.whitehouse.gov/omb/grants/spoc.html V. Application Content

Unless specifically indicated, this announcement requires submission of the following information:

A Project Abstract must be completed in the Grants.gov application forms. The Project Abstract must contain a summary of the proposed activity suitable for dissemination to the public. It should be a self-contained description of the project and should contain a statement of objectives and methods to be employed. It should be informative to other persons working in the same or related fields and insofar as possible understandable to a technically literate lay reader. This abstract must not include any proprietary/confidential information.

A Project Narrative must be submitted with the application forms. The project narrative must be uploaded in a PDF file format when submitting via Grants.gov. The narrative must be submitted in the following format:

· Maximum number of pages: 25. If your narrative exceeds the page limit, only the first pages which are within the page limit will be reviewed.

· Font size: 12 point unreduced, Times New Roman

· Double spaced

· Paper size: 8.5 by 11 inches

· Page margin size: One inch

· Number all narrative pages; not to exceed the maximum number of pages.

The narrative should address activities to be conducted over the entire project period and must include the following items in the order listed:

1. Understanding of the Public Health Burden and Impact

· Description of public health burden that the program will address

· Understanding of the need for this program and the planned activities within the target community

· Clear, concise descriptions and understanding of the requirements, objectives, and purpose of this FOA

2. Objectives

· Clear and measurable objectives to address the need and activities of this FOA;

· Indicators and Outcomes to be measured.

3. Methods

· Clear description of target population, case definition, case ascertainment methods, and methods for linking of data to validate cases and obtain additional demographic and outcome data;

· Clear description of the procedures for generation of the standardized data elements and process for the dissemination of quality data;

· Methods specific and feasible within the project timeframe.

4. Plan and Timeline

· Plan to carry out the proposed objectives;

· Ability to accomplish the program goals;

· Complete and comprehensive plan for the entire project period;

· Reasonable and achievable timeline to complete the activities in the specified project period;

· Description of ability to begin immediate implementation of the activities;

· Documentation of legal authority to access data sources needed to accomplish activities and goals;

· Description of planned collaboration with CDC, awardees, and appropriate partners.

5. Organizational and Personnel Capability

· Appropriate expertise and skills;

· Ability to identify and timely hire needed staff and consultants;

· Staff roles defined and sufficient to accomplish program goals.

6. Collaborations

· Appropriate and meaningful partners

· Ability to identify meaningful contractual agents or agencies

Additional information may be included in the application appendices. The appendices will not be counted toward the narrative page limit. This additional information includes:

· Budget (SF 424A) and Budget Narrative (Reviewed, but not scored): provide a detailed budget which identifies and describes the basis for the anticipated costs for personnel, fringe benefits, travel, supplies, equipment, contractual, consultants, indirect, and other items.

· Bona fide agent letter from state, if applicable

· Memorandum of Understanding (MOU) for subawards, consultants, partnering agreements, etc.

· Curricula Vitae/Resumes

· Letters of Support

· Organizational Charts

· Indirect Cost Rate Agreement

· Scientific articles and publications related to surveillance or DVT/PE research and prevention.

Additional information submitted via Grants.gov should be uploaded in a PDF file format, and should be named:

· Appendix 1 –Budget

· Appendix 2- Curriculum Vitae/Resumes

· Appendix 3 - Letters of Support, etc.

· Appendix 4 - Bona fide agent letter from state, if applicable

· Appendix 5 -.Memorandum of Understanding (MOU) for subawards, consultants, partnering agreements, etc.

· Appendix 6- Scientific articles and publications

· Appendix 7 - Other

No more than 30 should be uploaded per application Additional requirements for additional documentation with the application are listed in Section VII. Award Administration Information, subsection entitled “Administrative and National Policy Requirements.”

APPLICATION SUBMISSION

Registering your organization through www.Grants.gov, the official agency-wide E-grant website, is the first step in submitting an application online. Registration information is located on the “Get Registered” screen of www.Grants.gov. Please visit www.Grants.gov at least 30 days prior to submitting your application to familiarize yourself with the registration and submission processes. The “one-time” registration process will take three to five days to complete. However, the www.Grants.gov registration process also requires that you register your organization with the Central Contractor Registry (CCR) annually. The CCR registration can require an additional one to two days to complete.

Submit the application electronically by using the forms and instructions posted for this funding opportunity on www.Grants.gov. If the applicant encounters difficulty in accessing the forms on-line, contact the HHS/CDC Procurement and Grant Office Technical Information Management Section (PGO-TIMS) staff at (770) 488-2700 for further instruction.

Note: Application submission is not concluded until successful completion of the validation process.

After submission of your application package, applicants will receive a “submission receipt” email generated by Grants.gov. Grants.gov will then generate a second e-mail message to applicants which will either validate or reject their submitted application package. This validation process may take as long as two (2) business days. Applicants are strongly encouraged check the status of their application to ensure submission of their application package is complete and no submission errors exists. To guarantee that you comply with the application deadline published in the Funding Opportunity Announcement, applicants are also strongly encouraged to allocate additional days prior to the published deadline to file their application. Non-validated applications will not be accepted after the published application deadline date.

In the event that you do not receive a “validation” email within two (2) business days of application submission, please contact Grants.gov. Refer to the email message generated at the time of application submission for instructions on how to track your application or the Application User Guide, Version 3.0 page 57.

Other Submission Requirements

Letter of Intent (LOI):

Prospective applicants are asked to submit a LOI. The LOI does not need to be signed and should include the following information:

· Descriptive title of proposed project.

· Name, address, email address, and telephone number of the Principal Investigator/Project Director.

· A brief description of the planned statement of work. The narrative should be no more than two, double-spaced pages, printed on one side, with one-inch margins and 12-point unreduced, Times New Roman font.

· Names of other key personnel.

· Participating institutions/partners.

· Number and title of this funding opportunity.

LOI Submission Address: Submit the LOI by express mail, delivery service, fax, or E-mail to:

Michele G. Beckman, MPH CDC, NCBDDD, Division of Blood Disorders

1825 Century Boulevard Atlanta, GA 30345

Telephone: 404.498.6474 Fax: 404.498.6798 E-mail address: mbeckman@cdc.gov Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows CDC Program staff to estimate and plan the review of submitted applications.

LOIs should be provided not later than by the date indicated in the Section I entitled “Authorization and Intent”.

Dun and Bradstreet Universal Number (DUNS)

The applicant is required to have a Dun and Bradstreet Data Universal Numbering System (DUNS) identifier to apply for grants or cooperative agreements from the Federal government. The DUNS is a nine-digit number which uniquely identifies business entities. There is no charge associated with obtaining a DUNS number. Applicants may obtain a DUNS number by accessing the Dun and Bradstreet website or by calling 1-866-705-5711.

Electronic Submission of Application:

Applications must be submitted electronically at www.Grants.gov. Electronic applications will be considered as having met the deadline if the application has been successfully submitted electronically by the applicant organization’s Authorized Organizational representative (AOR) to Grants.gov on or before the deadline date and time.

The application package can be downloaded from www.Grants.gov. Applicants can complete the application package off-line, and then upload and submit the application via the Grants.gov Web site. The applicant must submit all application attachments using a PDF file format when submitting via Grants.gov. Directions for creating PDF files can be found on the Grants.gov Web site. Use of file formats other than PDF may result in the file being unreadable by staff.

Applications submitted through Grants.gov (http://www.grants.gov), are electronically time/date stamped and assigned a tracking number. The AOR will receive an e-mail notice of receipt when HHS/CDC receives the application. The tracking number serves as a receipt of submission.

If the applicant encounters technical difficulties with Grants.gov, the applicant should contact Grants.gov Customer Service. The Grants.gov Contact Center is available 24 hours a day, 7 days a week. The Contact Center provides customer service to the applicant community. The extended hours will provide applicants support around the clock, ensuring the best possible customer service is received any time it’s needed. You can reach the Grants.gov Support Center at 1-800-518-4726 or by email at support@grants.gov. Submissions sent by e-mail, fax, CD’s or thumb drives of applications will not be accepted.

Submission Dates and Times

This announcement is the definitive guide on LOI and application content, submission, and deadline. It supersedes information provided in the application instructions. If the application submission does not meet the deadline published herein, it will not be eligible for review and the applicant will be notified the application did not meet the submission requirements. The application face page will be returned by HHS/CDC with a written explanation of the reason for non-acceptance.

Letter of Intent (LOI) Deadline Date: April 26, 2010 30 DAYS AFTER DATE OF PUBLICATION IN GRANTS.GOV.

Application Deadline Date: May 11, 2010 45 DAYS AFTER DATE OF PUBLICATION ON GRANTS.GOV, 11:59pm Eastern Standard Time.

Explanation of Deadlines:

VI. Application Review Information

Eligible applicants are required to provide measures of effectiveness that will demonstrate the accomplishment of the various identified objectives of the cooperative agreement # CDC- RFA-DD10-1016. Measures of effectiveness must relate to the performance goals stated in the “Purpose” section of this announcement. Measures of effectiveness must be objective, quantitative and measure the intended outcome of the proposed program. The measures of effectiveness must be included in the application and will be an element of the evaluation of the submitted application.

Evaluation Criteria Eligible applications will be evaluated against the following criteria:

1. Understanding of the Public Health Burden and Impact (10 Points)

Did the applicant explain the public health burden that the program will address? To what extent does the applicant demonstrate understanding of the need for this program and the planned activities within the target community? Did the applicant adequately describe a clear, concise understanding of the requirements, objectives, and purpose of this FOA?

2. Objectives (15 Points)

Are the objectives clear and measurable to address the need and activities of this FOA? Do the objectives describe the proposed intent to conduct population-based surveillance of DVT and PE? Are the indicators and surveillance outcomes to be measured clearly stated and appropriate to achieve objectives of the FOA?

3. Methods (30 Points) Is there a clear description of target population, including documentation of a racially diverse population consistent with that of the U.S. population? Did the applicant fully describe their proposed case definition, case ascertainment methods, data sources and methods for linking of data to validate cases and obtain additional demographic and outcome data? Does the applicant clearly describe the procedures for generation of the standardized data elements and process for the dissemination of quality data? Are project methods specific and feasible within the project timeframe?

4. Plan and Timeline (30 Points) Is the plan adequate to carry out the proposed objectives and accomplish program goals within the specified timeline? Did the applicant document legal authority to access data sources needed to accomplish the activities in this FOA? Is there a description of planned collaboration with CDC, awardees, and appropriate partners?

5. Organizational and Personnel Capability (15 Points) Do the staff members have appropriate experience, expertise, and skills? Are the staff roles clearly defined? As described, will the staff be sufficient to accomplish the program goals?

Budget (SF 424A) and Budget Narrative (Reviewed, but not scored) Although the budget is not scored applicants should consider the following in development of their budget. Is the itemized budget for conducting the project, and justification reasonable and consistent with stated objectives and planned program activities?

If the applicants requests indirect costs in the budget, a copy of the indirect cost rate agreement is required. If the indirect cost rate is a provisional rate, the agreement should be less than 12 months of age. The indirect cost rate agreement should be uploaded as a PDF file with “Other Attachment Forms” when submitting via Grants.gov.

Funding Restrictions Restrictions, which must be taken into account while writing the budget, are as follows:

· Recipients may not use funds for research.

· Recipients may not use funds for clinical care.

· Recipients may only expend funds for reasonable program purposes, including personnel, travel, supplies, and services, such as contractual.

· Awardees may not generally use HHS/CDC/ATSDR funding for the purchase of furniture or equipment. Any such proposed spending must be identified in the budget.

· The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project objectives and not merely serve as a conduit for an award to another party or provider who is ineligible.

· Reimbursement of pre-award costs is not allowed.

The applicant can obtain guidance for completing a detailed justified budget on the CDC website, at the following Internet address:

http://www.cdc.gov/od/pgo/funding/budgetguide.htm.

Application Review Process

All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by NCBDDD and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements.

An objective review panel (CDC employees not located in the Division of Blood Disorders) will evaluate complete and responsive applications according to the criteria listed in Section VI. Application Review Information, subsection entitled “Evaluation Criteria”.

The objective review process will follow the policy requirements as stated in the GPD 2.04 at http://198.102.218.46/doc/gpd204.doc.

Applications Selection Process

CDC will provide justification for any decision to fund out of rank order. In addition, the following factors may affect the funding decision:

1. Diverse race/ethnic population included in the surveillance population to provide representation in data analyses.

2. Geographical diversity

VII. Award Administration Information Award Notices

Successful applicants will receive a Notice of Award (NoA) from the CDC Procurement and Grants Office. The NoA shall be the only binding, authorizing document between the recipient and CDC. The NoA will be signed by an authorized Grants Management Officer and e-mailed to the program director. A hard copy of the NoA will be mailed to the recipient fiscal officer identified in the application.

Unsuccessful applicants will receive notification of the results of the application review by mail.

Administrative and National Policy Requirements

Successful applicants must comply with the administrative requirements outlined in 45 Code of Federal Regulations (CFR) Part 74 or Part 92, as appropriate. The following additional requirements apply to this project:

· AR-7

Executive Order 12372

· AR-9

Paperwork Reduction Act Requirements

· AR-10

Smoke-Free Workplace Requirements

· AR-11

Healthy People 2010

· AR-12

Lobbying Restrictions

· AR-13

Prohibition on Use of CDC Funds for Certain Gun Control Activities

· AR-14

Accounting System Requirements

· AR-15

Proof of Non-Profit Status

· AR-21

Small, Minority, and Women-Owned Business

· AR-23

States and Faith-Based Organizations

· AR-24

Health Insurance Portability and Accountability Act Requirements

· AR-25

Release and Sharing of Data

· AR-26

National Historic Preservation Act of 1966

(Public Law 89-665, 80 Stat. 915)

· AR-27

Conference Disclaimer and Use of Logos

Additional information on the requirements can be found on the CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/Addtl_Reqmnts.htm.

For more information on the Code of Federal Regulations, see the National Archives and Records Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html CDC Assurances and Certifications can be found on the CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/grants/foamain.shtm

TERMS AND CONDITIONS

Reporting Requirements

Each funded applicant must provide CDC with an annual Interim Progress Report submitted via www.grants.gov:

1. The interim progress report is due no less than 90 days before the end of the budget period. The Interim Progress Report will serve as the non-competing continuation application, and must contain the following elements:

a. Standard Form (“SF”) 424S Form.

b. SF-424A Budget Information-Non-Construction Programs

c. Budget Narrative

d. Indirect Cost Rate Agreement

e. Project Narrative

f. Identify Estimated Unobligated Funds in the current budget period by component separately on the 424A Forms and provide detail actions to be taken to obligate the funds Additionally, funded applicants must provide CDC with an original, plus two hard copies of the following reports:

2. Financial Status Report (SF 269) and annual progress report, no more than 90 days after the end of the budget period.

3. Final performance and Financial Status Reports, no more than 90 days after the end of the project period.

These reports must be submitted to the attention of the Grants Management Specialist listed in the Section VIII below entitled “Agency Contacts”.

VIII. Agency Contacts

CDC encourages inquiries concerning this announcement.

For programmatic technical assistance, contact:

Michele Beckman, Project Officer Department of Health and Human Services

Centers for Disease Control and Prevention

NCBDDD, Division of Blood Disorders

1600 Clifton Rd. MS E-64

Atlanta, GA 30333

Telephone: 404.498.6474

E-mail: mbeckman@cdc.gov For financial, grants management, or budget assistance, contact:

Veronica Davis, Grants Management Specialist

CDC Procurement and Grants Office

2920 Brandywine Road, MS E09

Atlanta, GA 30341

Telephone: 770-488-2743

E-mail: YBG0@cdc.gov For general questions, contact:

Technical Information Management Section

CDC Procurement and Grants Office

2920 Brandywine Road, MS E-14

Atlanta, GA 30341

Telephone: 770-488-2700

Email:

pgotim@cdc.gov CDC Telecommunications for the hearing impaired or disabled is available at: TTY 770-488-2783.

Other Information

Information about the Division of Blood Disorders can be found at: www.cdc.gov/blooddisorders

PAGE